Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 1;14(1):140-142.
doi: 10.21037/hbsn-2024-642. Epub 2024 Dec 31.

Neoadjuvant immunotherapy for hepatocellular carcinoma: progress and perspectives

Lei Cai #  1 , Jun-Hong Chen #  2 , Jia-Hao Xu #  3 , Li-Hui Gu  3 , Ming-Da Wang  3 , Tian Yang  3
Affiliations
Editorial

Neoadjuvant immunotherapy for hepatocellular carcinoma: progress and perspectives

Lei Cai et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Hepatocellular carcinoma (HCC); immunotherapy; neoadjuvant therapy; pathological response; statistics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2024-642/coif). T.Y. serves as an unpaid editorial board member of HepatoBiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;77:1598-606. 10.1016/j.jhep.2022.08.021 - DOI - PMC - PubMed
    1. Yan WT, Li C, Yao LQ, et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobiliary Surg Nutr 2023;12:155-68. 10.21037/hbsn-21-288 - DOI - PMC - PubMed
    1. Vitale A, Cabibbo G, Iavarone M, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol 2023;24:e312-22. 10.1016/S1470-2045(23)00186-9 - DOI - PubMed
    1. Wang MD, Diao YK, Yao LQ, et al. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma. iLIVER 2024;3:100083.
    1. Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475-84. 10.1038/s41591-020-0829-0 - DOI - PubMed